CIR and OS from CR estimations at 36 months in the different RTK mutation and MRD patient subsets
| Patient subsets . | All patients . | t(8;21) . | inv(16)/t(16;16) . | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Patients (n) . | CIR (95% CI) . | OS from CR (95% CI) . | Patients (n) . | CIR (95% CI) . | OS from CR (95% CI) . | Patients (n) . | CIR (95% CI) . | OS from CR (95% CI) . | |
| RTK unmutated with 3-log MRD2 reduction | 84 | 18% (11-29) | 89% (79-94) | 50 | 19% (10-34) | 90% (77-96) | 34 | 17% (7-38) | 87% (65-96) |
| RTK mutated with 3-log MRD2 reduction | 38 | 33% (19-52) | 92% (76-97) | 19 | 31% (14-59) | 89% (63-97) | 19 | 35% (17-62) | 95% (68-99) |
| RTK unmutated without 3-log MRD2 reduction | 28 | 45% (28-67) | 83% (55-94) | 10 | 55% (28-86) | 73% (28-93) | 18 | 40% (20-68) | 90% (47-98) |
| RTK mutated without 3-log MRD2 reduction | 23 | 61% (40-83) | 56% (18-83) | 10 | 70% (37-96) | 53% (12-82) | 13 | 55% (29-83) | 60% (8-90) |
| Patient subsets . | All patients . | t(8;21) . | inv(16)/t(16;16) . | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Patients (n) . | CIR (95% CI) . | OS from CR (95% CI) . | Patients (n) . | CIR (95% CI) . | OS from CR (95% CI) . | Patients (n) . | CIR (95% CI) . | OS from CR (95% CI) . | |
| RTK unmutated with 3-log MRD2 reduction | 84 | 18% (11-29) | 89% (79-94) | 50 | 19% (10-34) | 90% (77-96) | 34 | 17% (7-38) | 87% (65-96) |
| RTK mutated with 3-log MRD2 reduction | 38 | 33% (19-52) | 92% (76-97) | 19 | 31% (14-59) | 89% (63-97) | 19 | 35% (17-62) | 95% (68-99) |
| RTK unmutated without 3-log MRD2 reduction | 28 | 45% (28-67) | 83% (55-94) | 10 | 55% (28-86) | 73% (28-93) | 18 | 40% (20-68) | 90% (47-98) |
| RTK mutated without 3-log MRD2 reduction | 23 | 61% (40-83) | 56% (18-83) | 10 | 70% (37-96) | 53% (12-82) | 13 | 55% (29-83) | 60% (8-90) |
Comparisons were based on cause-specific hazard Cox models, stratified on treatment arm and CBF subset when applicable, and the 12 patients who received allogeneic SCT in first hematological CR were censored at SCT time.
RTK, receptor tyrosine kinase (KIT and/or FLT3).